Descripción de la empresa
CollPlant Biotechnologies Ltd. operates within the healthcare sector, specifically focusing on the biotechnology industry through its specialized work in regenerative and aesthetic medicine. The company's core business involves the development and application of three-dimensional (3D) bioprinting technologies for tissues and organs, alongside medical aesthetics solutions deployed across the United States, Canada, Israel, Europe, and international markets. Its product portfolio is fundamentally derived from recombinant human collagen, positioning the firm as a key player in advanced tissue engineering and cosmetic dermatology. In terms of scale, the company holds a market capitalization of $5.18M and reports annual revenue of $2.37M over the trailing twelve months, employing a workforce of 39 individuals. These financial metrics indicate that CollPlant is a micro-cap entity with a relatively modest revenue base, suggesting that the company is likely in a development or early commercialization phase rather than a mature cash-generating stage. The small market cap relative to the biotechnology sector generally implies high potential volatility and significant risk, as the company has not yet achieved substantial profitability to support a larger valuation multiple. The limited headcount of 39 employees further underscores the lean operational structure typical of early-stage biotech firms attempting to scale complex scientific capabilities.
Salud financiera
The financial statements reveal a challenging operational environment characterized by a trailing twelve-month revenue of $2.37M contrasted sharply against a net income loss of $11,489,000 and an EBITDA deficit of $10,571,000. This substantial divergence between top-line revenue and net income highlights a highly aggressive cost structure, where operating expenses significantly outweigh gross profits, a common trait in capital-intensive biotechnology research and development. The company generated free cash flow of $-5,480,875, which indicates a continued burn rate that necessitates ongoing capital raising efforts or the utilization of existing cash reserves to maintain operations. Despite the negative cash flow, the company maintains a cash balance of $5.59M against total debt obligations of $2.85M, providing a liquidity buffer, though the high debt-to-equity ratio of 46.80 suggests a leveraged balance sheet rather than a conservative one. Liquidity management appears robust in the short term, supported by a current ratio of 2.52, which signifies that current assets are more than double current liabilities, ensuring the ability to meet short-term obligations without immediate distress. However, the return on equity stands at -117.6% and the return on assets is -48.7%, metrics that collectively reveal that management effectiveness in generating value is currently negative, as the company destroys shareholder value through its ongoing operational losses.
Evaluación de valoración
Valuation multiples for CollPlant reflect its unprofitable status, with a trailing P/E ratio marked as N/A due to the absence of earnings, while the forward P/E is calculated at -0.92, implying that expected future earnings are projected to remain negative or are insufficient to justify a positive multiple based on current pricing. The price-to-book ratio is recorded at 0.76, indicating that the market values the company at a discount to its net asset book value, a scenario often seen in distressed or highly speculative biotech stocks where intangible assets may not be fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.18 and an EV/EBITDA of -0.23 suggest that investors are pricing the stock based on revenue potential and market share prospects rather than current earnings power. The stock has experienced significant price volatility within the past year, trading between a 52-week high of $4.98 and a 52-week low of $0.35, placing the current price well below the yearly peak. The beta coefficient of 0.94 indicates that the stock's price volatility moves in tandem with the broader market, exhibiting slightly less sensitivity than the market average but still presenting high risk for conservative portfolios.
Growth & Income
Growth metrics demonstrate a contractionary trend, with revenue growth year-over-year declining by -63.4% and earnings growth marked as N/A due to the lack of prior period profitability for meaningful comparison. The decline in revenue growth relative to earnings implies that the company is struggling to maintain its sales momentum, potentially due to market saturation, product delays, or reduced demand in its primary markets of medical aesthetics and regenerative medicine. As a non-dividend payer, CollPlant offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning the company retains all of its minimal earnings and cash flow to fund operations, R&D, and growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for micro-cap biotechnology firms that prioritize expanding their technological footprint over providing current income to investors. Overall, the growth and income profile of CollPlant Biotechnologies Ltd. is defined by significant revenue contraction and a complete absence of dividend income, reflecting the high-risk, high-reward nature of early-stage biotechnology investments where capital preservation is often secondary to product development and market penetration.